Chemical Information | |
Antiviral agent ID | DrugRepV_5320 | |
Antiviral agent name | 4,5-dimethyl 1-[(2R,5S)-3,4-bis(acetyloxy)-5-[(acetyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate | |
IUPAC Name | 4,5-dimethyl 1-[(2R,5S)-3,4-bis(acetyloxy)-5-[(acetyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate | |
SMILES (isomeric) | COC(=O)C1=C(N(C=N1)[C@@H]1O[C@@H](COC(C)=O)C(OC(C)=O)C1OC(C)=O)C(=O)OC | |
Molecular Formula | C18H22N2O11 | |
Molecular Weight (g/mol) | 442.377 | |
InChl | InChI=1/C18H22N2O11/c1-8(21)28-6-11-14(29-9(2)22)15(30-10(3)23)16(31-11)20-7-19-12(17(24)26-4)13(20)18(25)27-5/h7,11,14-16H,6H2,1-5H3/t11-,14?,15?,16+/s2 | |
Structural Information | |
|
|
Clinical Information | |
Biological Information | |
Secondary Indication | Severe acute respiratory syndrome coronavirus (SARS-CoV) NA NA | |
Secondary Indication (Approaches) | Experimental | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Model system) [cell lines/ animal models] | Vero
| |
Secondary Indication (Mode of viral infection) | Adsorption
| |
Secondary Indication (Viral titer) | 0.01 MOI
| |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Time of drug delivery) | Post infection
| |
Secondary Indication (Duration of drug delivery) | 2 days
| |
Secondary Indication (Drug concentration) | 40 μg/mL
| |
Secondary Indication (Cell based assay) | Real-time PCR
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | IC50 [ 50 % ] | |
Secondary Indication (Cytotoxicity) | 75 μg/ml | |
Reference | Gunther S, Asper M, Roser C, Luna LK, Drosten C, Becker-Ziaja B, Borowski P, Chen HM, Hosmane RS..Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus a.Antiviral Res. 2004 Sep;63(3):209-15. PMID:15451189
| |
Comment | Small-scale screening identified a class of imidazole nucleoside/nucleotide analogues with antiviral activity against Lassa virus. The analogues contained either dinitrile or diester groups at the imidazole 4,5-positions, and many of which possessed an acyclic sugar or sugar phosphonate moiety at the imidazole 1-position.
| |